Speakers

Silvia-Elena Glont is a Senior Scientist at AstraZeneca (Cambridge, UK), with a strong background in molecular biology and cancer research.  She earned her PhD at Cancer Research UK Cambridge Institute / University of Cambridge, where her doctoral work uncovered novel molecular mechanisms underlying endocrine resistance in ER-positive breast cancer — including the discovery of the transcriptional co-factor ETV6 driving tamoxifen resistance, and the identification of potential repurposable therapies via a screen of FDA-approved drugs.  Her earlier work includes key studies establishing that the pioneer transcription factor FOXA1 operates independently of hormonal signalling — challenging prevailing assumptions about hormone-receptor dynamics in cancer. With a track record of rigorous genomic and proteomic research, Silvia brings deep expertise in chromatin biology, transcriptional regulation and drug response mechanisms — making her a strong voice in translational cancer research and therapeutic development.